RIO DE JANEIRO, BRAZIL - Brazilian pharmaceutical company União Quimica plans to press ahead with production of Russia’s Sputnik V vaccine with a view to exporting it to other parts of South America.
It and Russian sovereign wealth fund RDIF, which is marketing Sputnik V for Russia’s Gamaleya Institute, last week filed for emergency use approval from Brazilian health regulator Anvisa, but were told more documentation was needed.
The company’s international business director, Rogerio Rosso said a new meeting was scheduled with Anvisa on Thursday.
However, “we do not need to have the vaccine registered in Brazil . . .